India Globalization Capital Inc. (NYSE: IGC) has two lines of business, a legacy infrastructure business and a medical cannabis business that has developed a flagship product for Alzheimer’s patients. Also, the Company recently announced that it would develop and commercialize a hemp/CBD infused energy drink. The company is based in Maryland, U.S.A.

 

On October 15, 2018, the company announced financial results for the quarter ended September 30, 2018, which is the second quarter of its 2019 fiscal year.

 

Increasing revenue from legacy business: Total revenue was approximately $811 thousand for the three months ended September 30, 2018, an increase of 245% as compared to approximately $235 thousand for the three months ended September 30, 2017. All quarterly revenue was attributable to the legacy infrastructure business operations.

 

Comfortable liquidity: From a liquidity and financial standpoint, at the end of September 30, 2018, the Company had approximately $6.41 million in cash and cash equivalents. The management believes that it has adequate financial resources to fund its short-term objectives including, among others, marketing HyalolexTM, developing and commercializing its recently announced drink formulation, expanding the depth of its complementary cannabis medication and product portfolio, initiating filings with the Food and Drug Administration (FDA), and conducting small clinical trials as appropriate in support of its product pipeline.

_____________________________________________________________________

Our members have booked up to 800% with our recent (2018) NASDAQ and NYSE small cap alerts. We will be initiating coverage on another exciting small cap security this week this week (10/23/18) at 9:45 AM EST. View our recent picks, track record, long term biotech picks and sign up for our real time, low float and breakout mobile/text alerts here – https://tradersnewssource.com/traders-news-source-new-members/

_____________________________________________________________________

Key investment highlights of IGC:

• IGC Management’s focus is to develop and commercialize cannabinoid-based alternative therapies for indications such as Alzheimer’s disease, Parkinson’s disease, and pain. The company’ flagship product is Hyalolextm, and it is a cannabinoid-based alternative oral combination therapy whose active ingredients have been shown to help alleviate symptoms associated with Alzheimer’s disease. (not yet approved by FDA though)
• With Hyalolex, the management expects revenue in the fiscal year 2019, though there can be no assurance as to the amount of such revenue and or full-fledged commercialization.
• The Company recently entered the hemp oil/cannabidiol (CBD) infused beverage space and expects to bring a sugar-free CBD infused energy drink to market.
• The Company has filed several patents for its pipeline of products including ones for the treatment of Alzheimer’s, Parkinson’s and Central Nervous System related disorders, pain, eating disorders, seizures in cats and dogs, and an energy drink.
• Besides, since inception, the Company operates a legacy business that involves trading commodities and heavy equipment rental. The company’ present revenue currently comes only from its legacy business.

Source: company’ filings

 

About the Company: India Globalization Capital, Inc. (“IGC”), a Maryland corporation, was organized on April 29, 2005 formed for acquiring one or more businesses with operations primarily in India, Hong Kong, China and now Malaysia, through a merger, capital stock exchange, asset acquisition or other similar business combination or acquisition. On March 8, 2006, the Company completed an initial public offering. IGC is headquartered in the United States. The operations of IGC are based in USA, India, and Malaysia.

 

Recent announcements by the company:

• IGC Files Provisional Patent to Protect IP for CBD-Infused Energy Drink: On October 9, 2018, the company announced that it had filed a provisional method and composition patent application (IGC-509) with the U.S. Patent and Trademark Office for the treatment of fatigue and energy restoration. This filing is one of a series of steps in the Company’s development and commercialization plan to support the creation of a branded, hemp/CBD sugar-free energy drink, which was previously disclosed by the Company on September 25, 2018.
• IGC to Enter the Hemp/CBD-Infused Energy Drink Space: On September 25, 2018, the company announced that it had executed a distribution and partnership agreement for several products including a sugar-free, energy drink called ‘Nitro G.’ IGC will pay 797,000 shares of restricted, unregistered, common stock, for a 10-year agreement, with an option for multiple 5-year extensions, for the rights to market the products in the U.S., Canada, Mexico, and South America and exclusive global rights to all developed CBD-infused products. IGC plans to create a branded, hemp/CBD-infused version of the formulation that addresses market demand for energy drinks with the inclusion of healthy properties derived from hemp including CBD.
• India Globalization Capital Raises $1 Million in Direct Equity Investment to Support Hyalolex Commercialization: On September 12, 2018, the company announced that it raised $1.0 million in a private placement of restricted shares. The net proceeds from the offering are for marketing and working capital associated with the commercialization of Hyalolextm. Bradbury Investment Fund makes the investment limited, based in Hong Kong, through three of its Global Asset Funds. The investment is strategic as the fund can introduce the Company to potential acquisitions of global assets as more countries legalize hemp, cannabinoids, and cannabis. Further, the fund can also help the Company in introducing its products, including Hyalolextm, in foreign countries
• IGC to Enter California Market with Hyalolex: On August 14, 2018, the company announced that it had designated California as a priority market for Hyalolex, its lead cannabis-based supplement for treating and managing Alzheimer’s patients. The cannabis market is showing explosive growth, and IGC is aggressively moving forward with the company’ vision of owning and marketing the leading brands for large medical indications such as Alzheimer’s, Parkinson’s, PTSD, pain, veterinary medicine, and cancer. With eight patents filed, IGC has made significant strides towards achieving these goals and building value for the shareholders as an NYSE American listed company.

 

About the industry/demand drivers:

• According to a Grand View Research forecast, the global energy drinks market is projected to be almost $85 billion by the year 2025, with non-alcoholic beverage sales expected to account for a significant portion of the market. This represents a unique opportunity for the development and commercialization of a CBD-infused, sugar-free energy beverage.
• California is considered to be the largest addressable U.S. market for cannabis with an environment that strongly embraces its acceptance. This represents a significant opportunity for Hyalolex and other brands, as such the company is currently coordinating the necessary steps to efficiently and rapidly introduce its product to high-density regions in the state. It should be noted that according to U.S. Census data, California has an estimated population of 39.54 million and that total is larger than all of Canada. IGC’s management team has been actively meeting with California-based manufacturers and distributors to assemble the requisite combination of partners to efficiently bring Hyalolex to dispensaries, patients, and caregivers in California. The company’ “Drops of Clarity” marketing program will highlight the potential benefits of Hyalolex as a supplement to cannabis physicians as well as to caregivers and patients via both a digital format and through grassroots outreach.

 

Financial Results:

• Revenue: Total revenue was about $811 thousand and about $235 thousand for the three months ended September 30, 2018, and 2017, respectively. This represents an increase in revenue of about $576 thousand or about 245 %.  In the three-month period ended September 30, 2018, the company revenue arose from trading commodities and the equipment rental businesses.  The increase in total revenue is attributable to an increase in the volume of trading in different types of steel and other infrastructure related material in and outside of India. The company’ focus in the current year is to increase margins and further de-risk the trading business.
• Profitability: Net loss was about $858 thousand and about $304 thousand for the three-month periods ended September 30, 2018, and 2017, respectively. The $554 thousand increase in loss (182 % increase) is attributable to an increase in SG&A.
• Liquidity and financial flexibility: At the end of September 30, 2018, the Company had about $6.41 million in cash and cash equivalents. In the quarter ended September 30, 2018, the non-GAAP total cash burn after adjusting for non-cash items that include ESOPs and other payments made with common stock, is about $506 thousand.
• The cash burn is primarily associated with public company expenses, increased product R&D, production, and getting Hyalolextm ready for market, among others. The Company believes that it has adequate financial resources to meets its short-term goals including marketing Hyalolex, developing and marketing a drink formulation, marketing several other complimentary medications, initiating filings with the FDA and conducting small clinical trials, amongst others.

 

Key risk factors and potential stock drivers:

Stock Performance:

• The favorable outcome of clinical testing and its path to FDA approvals could be a medium-term trigger for IGC stock.
• That said, notwithstanding, incremental/recent developments; the company’s meaningful value (on a long run) would still be far-fetched in its targeted business streams. The company’ business operations are still at a very early stage, and present revenue is driven only by its legacy business.
• The company has changed its business strategies in the past. Therefore, management’ ability to ramp up operations and actually demonstrate a track record of revenue/profitability would continue to remain crucial.
• The company’s business risk profile is subject to significant regulatory risk. Cannabis remains illegal under U.S federal law, and therefore, strict enforcement of federal laws regarding medical-use cannabis would likely result in slower growth of the company business plans, and/or delisting from the NYSE American.
• The company’s ability to ramp-up profitability while sustaining its revenue growth would be one of the key stock drivers over the near to medium term. Additionally, the company should regulate its development and other indirect costs.

 

Stock Chart:

 

• On Friday, Oct 19th, 2018, IGC closed at $3.18, with a robust average volume of 14.7 million shares exchanging hands. Market capitalization is $115.586 million. The current RSI is 45.74
• In the past 52 weeks, shares of IGC have traded as low as $0.36 and as high as $14.58
• At $3.18, shares of IGC are trading around its 50-day moving average (MA) at $2.83 and above its 200-day moving average (MA) at $1.19
• The present support and resistance levels for the stock are at $2.29 & $4.59 respectively.

 

 

Disclaimer

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.

We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.

When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.

17B Disclosure

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.

Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.